SOURCE: LipidViro Tech, Inc.

April 27, 2007 09:00 ET

LipidViro Tech, Inc. to Present at Financial Services Exchange Investment Conference to Discuss Potential for New Treatment for Stroke and Chronic Heart Failure

SALT LAKE CITY, UT -- (MARKET WIRE) -- April 27, 2007 -- LipidViro Tech, Inc. (OTCBB: LPVT), a medical device company developing its proprietary d-OSAB technology for the treatment of stroke and chronic heart failure, announced that J.S. Latino, co-founder and head of research, and Linda Sharkus, Ph.D., director, are attending the Financial Services Exchange (FSX) Investment Conference being held April 26-28, 2007, at the Hilton San Francisco Financial District Hotel in San Francisco.

Mr. Latino is scheduled to make a formal presentation this morning and will also hold one-on-one meetings throughout the three-day conference.

FSX investment conferences provide a forum for companies to discuss their businesses, growth strategies, and outlook with key decision makers for independent broker/dealers and investment firms nationwide seeking opportunities to invest in or finance small-cap and emerging growth companies.

As an adjunct to the conference, Steve Crowley, a noted national radio broadcaster and host of "Steve Crowley's American Scene," one of the most successful, national, financial talk-radio programs in America, interviewed Mr. Latino. The live broadcast aired yesterday at 7:06 AM (PDT)/10:06 AM (EDT) and will be archived at The Money Channel (http://archives.warpradio.com/btr/AmericanScene/042610.MP3) for fourteen days.

About LipidViro Tech, Inc.

LipidViro Tech is a development-stage medical device company engaged in research and commercial development of a multi-therapeutic device-based platform to treat ischemic brain stroke and chronic heart failure, diseases with few viable treatment options and markets exceeding $20 billion annually in the U.S. and EU. Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, more than 1.7 million people in the U.S. and EU become victims of stroke. The single approved therapeutic for ischemic brain stroke patients is Tissue Plasminogen Activator (tPA), but patients are eligible for tPA only during a three-hour window from time of stroke; tPA use after three hours causes bleeding in the brain which may prove fatal. Consequently, only 6% of U.S. stroke patients and less than 1% of EU stroke patients utilize tPA. Anecdotal data suggests d-OSAB may be an effective stroke therapeutic targeting the majority of patients untreated. During 2007, the Company is scheduled to commence a 100-patient Phase IIa study treating patients who have suffered an ischemic brain stroke to confirm these clinical findings.

Contact Information